MedTrace Logo

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

NCT04603872 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2020-10-28

No results posted yet for this study

Summary

A Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma.

Conditions

  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Acute Lymphoblastic Leukemia, in Relapse
  • Acute Lymphocytic Leukaemia Refractory
  • Non-Hodgkin's Lymphoma, Relapsed
  • Non-Hodgkin's Lymphoma Refractory

Interventions

DRUG

CD19/BCMA Targeted CAR T-cells and dasatinib

Each subject receive CS1 Targeted CAR T-cells by intravenous infusion, and the dasatinib was combined according to the presumed regimens.

DRUG

CD19/BCMA Targeted CAR T-cells

Each subject receive CS1 Targeted CAR T-cells by intravenous infusion.

Sponsors & Collaborators

  • Yake Biotechnology Ltd.

    collaborator INDUSTRY

  • Zhejiang University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2023-11-01
Completion
2026-11-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04603872 on ClinicalTrials.gov